Fleischhacker W W
Abteilung für Biologische Psychiatrie, Universitätsklinik für Psychiatrie, Innsbruck.
Wien Med Wochenschr. 1998;148(11-12):266-72.
A number of novel antipsychotics were registered and introduced into clinical practice in the last decade. These include olanzapine, quetiapine, risperidone, sertindole and zotepine as well as ziprasidone, which is still in the registration process. It quickly became apparent, that it is not always easy to translate results from phase II and III clinical trials into everyday clinical practice. In this context, we discuss methodological aspects that mainly deal with selection of patients for clinical trials and clinical trial methodology. Next to that, an overview of the current knowledge concerning novel antipsychotics is given. There is no doubt that these drugs broaden the therapeutic spectrum made available to patients suffering from schizophrenia. On the other hand, it is evident that there is still a need for a critical evaluation of the risk-benefit-ratio of novel antipsychotics. Clinical psychiatrists also face the challenge to modify some of the traditional treatment approaches. These prerequisites will allow the embedding of novel antipsychotics into modern integrative treatment concepts of schizophrenia.
在过去十年中，多种新型抗精神病药物获批并应用于临床实践。这些药物包括奥氮平、喹硫平、利培酮、舍吲哚和氯氮平，以及仍在审批过程中的齐拉西酮。很快就发现，将II期和III期临床试验的结果转化为日常临床实践并非总是易事。在此背景下，我们讨论主要涉及临床试验患者选择和临床试验方法的方法学问题。除此之外，还概述了有关新型抗精神病药物的现有知识。毫无疑问，这些药物拓宽了精神分裂症患者可获得的治疗范围。另一方面，显然仍需要对新型抗精神病药物的风险效益比进行批判性评估。临床精神科医生也面临着修改一些传统治疗方法的挑战。这些前提条件将有助于将新型抗精神病药物纳入现代精神分裂症综合治疗理念。
